Nektar Therapeutics (NKTR)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-07) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-12) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-06) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-07) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-08) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-12) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-07) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-08) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-09) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-04) · 99.1 | 8-K (2024-01-10) | ||
| 10-Q | Q3-2023 | 8-K (2023-11-07) · 99.1 | ||
| 10-Q | Q2-2023 | 8-K (2023-08-08) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations | ||
| Consolidated Statements of Operations (P) | ||
| Consolidated Statements of Comprehensive Loss | ||
| Condensed Consolidated Statements of Stockholders' Equity (deficit) | — |
|
| Consolidated Statements of Stockholders Equity | ||
| Condensed Consolidated Statements of Stockholders' Equity (deficit) (P) | — |
|
| Consolidated Statements of Stockholders' Equity (P) | — |
|
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Cash Flows (P) | ||
| Notes | ||
| Award Timing Disclosure | — |
|
| Cash and Investments In Marketable Securities | ||
| Commitments and Contingencies | ||
| Consolidated Financial Statement Details | ||
| Cybersecurity Risk Management, Strategy, and Governance | — |
|
| Equity Method Investment | ||
| Gain On Sale of The Huntsville Manufacturing Facility | — |
|
| Impairment of Goodwill | ||
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Liabilities Related To The Sales of Future Royalties | — |
|
| License and Collaboration Agreements | ||
| Operating Leases | — |
|
| Organization and Summary of Significant Accounting Policies | ||
| Organization, Summary of Significant Accounting Policies and Key Transactions | — |
|
| Pay Vs Performance Disclosure | ||
| Pre-funded Warrant | ||
| Restructuring and Impairment | ||
| Restructuring, Impairment and Costs of Terminated Program | ||
| Restructuring, Impairment and Costs of Terminated Program, and Impairment of Goodwill | — |
|
| Segment Reporting | ||
| Stock-based Compensation | ||
| Stockholders" Equity | — |
|
| Stockholders' Equity | ||
| Subsequent Events | ||